Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
E2F-8 CRISPR/Cas9 KO Plasmid (h): sc-406972
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- E2F-8 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the E2F-8 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: E2F-8 Antibody (B-9): sc-514064
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
E2F-8 CRISPR/Cas9 KO Plasmid (h) | sc-406972 | 20 µg | $397.00 |
Overview
E2F8 encodes E2F-8, an atypical member of the E2F transcription factor family that primarily functions as a transcriptional repressor controlling cell-cycle progression and DNA replication timing. E2F-8 participates in RB/E2F-regulated networks, coordinates S-phase gene expression, and contributes to maintenance of genome stability through regulation of proliferative programs. It has roles in developmental growth control and cell fate decisions, and altered E2F8 expression has been linked to dysregulated proliferation observed across multiple cancer contexts. Because E2F-8 interfaces with core checkpoint and replication-associated pathways, it is a useful node for studying transcriptional control of cell-cycle entry and replication stress responses.
E2F-8 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the E2F8 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the E2F8 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the E2F8 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish E2F-8 protein expression.
This CRISPR knockout system enables efficient generation of E2F8-deficient cell models for investigation of E2F-8 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting E2F8 exon(s) critical for E2F-8 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple E2F8 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by E2F-8 CRISPR/Cas9 KO Plasmid (h) and E2F-8 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the E2F8 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by E2F-8 HDR Plasmid (h) and E2F-8 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by E2F8 homology arms to support homology-directed repair at defined E2F8 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.